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Abstract
Summary Osteoporosis is a common complication of androgen deprivation therapy (ADT). In this large Swedish cohort study
consisting of a total of nearly 180,000 older men, we found that those with prostate cancer and ADT have a significantly
increased risk of future osteoporotic fractures.
Introduction Androgen deprivation therapy (ADT) in patients with prostate cancer is associated to increased risk of fractures. In
this study, we investigated the relationship between ADT in patients with prostate cancer and the risk of incident fractures and
non-skeletal fall injuries both compared to those without ADT and compared to patients without prostate cancer.
Methods We included 179,744 men (79.1 ± 7.9 years (mean ± SD)) from the Swedish registry to which national directories were
linked in order to study associations regarding fractures, fall injuries, morbidity, mortality and medications. We identified
159,662 men without prostate cancer, 6954 with prostate cancer and current ADT and 13,128 men with prostate cancer without
ADT. During a follow-up of approximately 270,300 patient-years, we identified 10,916 incident fractures including 4860 hip
fractures.
Results In multivariable Cox regression analyses and compared to men without prostate cancer, those with prostate cancer and
ADT had increased risk of any fracture (HR 95% CI 1.40 (1.28–1.53)), hip fracture (1.38 (1.20–1.58)) and MOF (1.44 (1.28–
1.61)) but not of non-skeletal fall injury (1.01 (0.90–1.13)). Patients with prostate cancer without ADT did not have increased risk
of any fracture (0.97 (0.90–1.05)), hip fracture (0.95 (0.84–1.07)), MOF (1.01 (0.92–1.12)) and had decreased risk of non-
skeletal fall injury (0.84 (0.77–0.92)).
Conclusions Patients with prostate cancer and ADT is a fragile patient group with substantially increased risk of osteoporotic
fractures both compared to patients without prostate cancer and compared to those with prostate cancer without ADT.We believe
that this must be taken in consideration in all patients with prostate cancer already at the initiation of ADT.
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Introduction
There is continuing evidence that men, although present-
ing with apparent risk factors for osteoporotic fractures
such as previous fragility fractures or treatment with glu-
cocorticoids, are not evaluated properly or treated for os-
teoporosis to the same extent as women [1, 2]. Although
the life-time risk of sustaining a fragility fracture is lower
in men than in women [3], the male life expectancy is
constantly increasing [4] which is expected to result in
increased fracture burden in the future. Furthermore, male
patients appear to remain at higher risk of mortality fol-
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One large male high-risk group that could easily be detect-
ed are those with prostate cancer and androgen deprivation
therapy (ADT). Prostate cancer is indeed the most frequently
diagnosed malignancy in men [6] and the majority are diag-
nosed in developed countries [7]. ADT as a treatment of met-
astatic prostate cancer has been increasing over time [8] and
may include gonadotropin-releasing hormone (GnRH) ana-
logues, androgen receptor blockers or a combination of the
two. The effects of ADT are mediated through suppression
of testosterone to castrate levels which further leads low levels
of oestrogen and a state of severe hypogonadism. Indeed, the
low serum oestrogen in hypogonadal men seems to have an
effect on bone density, comparable with that for postmeno-
pausal women [9]. Studies have shown that hypogonadism
together with alcohol abuse and glucocorticoid excess are
the most common causes of male osteoporosis [10]. A recent-
ly published meta-analysis confirmed that patients with pros-
tate cancer and ADT have a high prevalence of osteoporosis
[11], and similar to glucocorticoids, there is a rapid bone loss
during the first 6–12months of therapy [12]. This indicates the
importance of identifying and risk-evaluating these patients at
an early stage, probably as a routine already when considering
ADT.
The relationship between treatment with ADT and in-
creased risk of osteoporotic fractures was initially published
more than 20 years ago [13] and subsequently confirmed by
several studies [14–18]. However, large studies where patients
are compared to the normal population and where adjustment
has been made for traditional risk factors for fragility fractures
included in fracture risk assessment tools (such as FRAX [19])
are missing.
Therefore, the aim of this study was to investigate the re-
lationship between ADT in patients with prostate cancer and
the risk of incident fractures compared to patients without
prostate cancer and compared to those with prostate cancer
but without ADT, adjusted for traditional risk factures for
osteoporotic fractures including the risk of falling.
Methods
Study design
We included a total of 179,744 men (79.1 ± 7.9 years (mean ±
SD)) from the recently collected “Fractures and fall injuries in
the elderly cohort” (FRAILCO) which is a patient-based co-
hort study where Swedish national directories are linked in
order to study associations regarding fractures, fall injuries,
morbidity, mortality, and medications [20–22]. The cohort
was collected between 2008 and 2014 to the Swedish national
directory “Senior Alert” [23], and the included individuals
were followed from the time of registration until death, emi-
gration, or at the end of 2014. The directory was originally
designed to serve as a quality registry to support improve-
ments in preventive care for older adults and includes over
20% of the entire Swedish population in this age group.
Swedish citizens, 65 years or older were registered in connec-
tion to a visit to a healthcare facility by a licenced allied health
professional, regardless of diagnosis, comorbidities, function-
ing, and health. In the end of 2014, more than 90% of all
municipalities in Sweden were linked to Senior Alert, and
all participants were registered with information about age,
sex, height and weight along with several parameters related
to the risk of falling, pressure ulcers and nutrition. Information
concerning medications, diagnoses, fall injuries, fractures and
deaths, in relation to time of registration, were collected using
the Drug Dispensation Register (2005–2014), the Patient
Register (2001–2014 for outpatient visits and 1987–2014 for
admitted patients) and Cause of Death Register. Information
regarding immigration and emigration was included from
Statistics Sweden. The study was approved by the regional
ethical review board in Gothenburg.
Definition of patient groups
The study population of the present study is presented in
Fig. 1. Patients were defined as having prostate cancer if they
had received ICD code C61 in the Patient register which in-
cludes all admitted patients between 1987 and 2014 and all
outpatient visits between 2001 and 2014. We further defined
patients with prostate cancer as having received ADT if they
had any previous prescriptions of a GnRH-agonist with a
treatment period of at least 3 months and no more than 1 year
since the last dose in the Drug dispensation register (2005–
2014). Usage of antiandrogen, alendronate or calcium + vita-
min D supplements was defined as any previous prescription
of the drug in the register. No information regarding surgical
orchidectomy, radiation therapy, Gleason score or presence of
skeletal metastases was available in the investigated data-
bases. Patients with prescriptions of GnRH-agonist but with-
out a diagnosis of prostate cancer (n = 2287) were excluded
from the study cohort.
Definition of outcomes
Fracture information was collected from the National Patient
Register, and all non-malignant fracture diagnoses (apart from
head fractures) regardless of type of trauma were included.
Incident hip fracture was defined as a fractured femoral head,
neck, trochanter or subtrochanteric part of femur that occurred
after the registration in Senior Alert and that was accompanied
with a code for surgical procedure (ICD: S720-S722 in com-
bination with surgical procedure starting with NFB or NFJ39-
NFJ99). Incident major osteoporotic fracture (MOF) was de-
fined as a fracture of the hip, vertebrae, upper- or lower arm
(S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T08, T10,
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T12, T142, M485). To further ascertain that the defined codes
represented an incident fracture and not a previous fracture
with a revisit; the second fracture was discarded if the codes
were repeated within 5 months. Incident non-skeletal fall in-
jury was classified as any injury (except fractures) occurring
after the time of inclusion, that was accompanied by a code
representing a fall (S00-T14 (except S12, S22, S32, S42, S52,
S62, S72, S82, S92, T02, T08, T10, T12, T142, M485) + code
representing a fall (W00-W19)).
Definition of traditional risk factors for fracture
Age, weight and height were registered in all patients at inclu-
sion in Senior Alert. We did not have information regarding
smoking status in the databases. Previous fracture was defined
as any previous diagnosis of a prior fracture according to ICD-
codes stated in previous section and rheumatoid arthritis as the
presence of the diagnosis according to ICD-codes M05-06.
Previous glucocorticoid treatment was defined as any previ-
ous period the patient had retrieved prescriptions for more
than 450 mg of prednisolone or equivalents over a period of
3 months or more, a dose corresponding to a daily treatment of
at least 5 mg prednisolone for 3 months. Secondary osteopo-
rosis was defined as the presence of diagnoses of insulin-
dependent diabetes (E10), hyperthyroidism (E05),
hypogonadism (E28-29), malnutrition (E40-46), osteogenesis
imperfecta (Q780) or chronic liver disease (K70-77). Over-
consumption of alcohol was estimated according to several
diagnoses of alcohol abuse together with alcohol-related dis-
eases according to ICD-codes (F10, G312, G621, G721, I426,
K292, K70, K852, K860, T51, Y912, Y913).We did not have
any measurements of bone mineral density in the databases,
and the diagnosis of osteoporosis is very rare in the Patient
Registry and could not be reliably studied.
Definition of comorbidities and general health
For some analyses, Charlson comorbidity index [24] was
used to quantify comorbidity. The index was calculated as
a weighted sum of the following diseases: One point each
for dementia (F00-F03), ischemic heart disease (I20-I25),
congestive heart failure (I50), cerebrovascular disease
(I60-I69), disease of arteries, arterioles and capillaries
(I70-I79), chronic pulmonary disease (J43-J46), chronic
liver disease (K70-K77); one point for mild renal failure
(N17-N19) and an extra point if moderate or severe renal
failure (N182-N185); one point for diabetes (E10-14) and
an extra point if diabetes with end organ damage (E102,
E103, E104, E105, E107, E112, E113, E114, E115, E117,
H360, H360A, H360B, H360X); two points each for
hemiplegia (G81), peptic ulcer disease (K25-K27), tu-
mour without metastasis (C00-C76, C80, C97),
The FRAILCO cohort
(n = 429 313)
Paents with risk assessments 
2008-2014
(n = 433 195)
Non prostate cancer
(n = 159 662)
Prostate cancer
without GnRH-agonist





(n = 247 282)
Excluded
GnRH-agonist without
diagnosis of Prostate cancer
(n = 2287)
Excluded
3882 paents excluded due to :
• Faulty mortality data (260)
• Late immigraon, aer 2004 (2240)
• Emigraon, before study inclusion (368)
• Unreliable registraon of (*) weight, 
height or BMI (1369)
Fig. 1 Flow chart of the entire
cohort. Asterisk indicates
accepted values after exclusion of
top and bottom 1‰ were weight,
30–176 kg; height, 114–197 cm
and BMI, 12,23–73,05 kg/m2
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lymphoma or leukaemia (C81-C96) and six points for
metastatic solid tumour (C77-C79). From the senior alert
questionnaire, 98.9% of the registered individuals provid-
ed information regarding previous known falls (yes/no)
which was used as a surrogate marker for risk of falling.
Characterisation of general condition, food and liquid in-
take at the time of risk assessment was performed using
questions from the validated RAPS or Norton scales [25]
used in Senior Alert for risk assessment of decubitus
ulcers.
Statistical analysis
Age and BMI are presented as mean ± SD, follow-up
time and time since diagnosis of prostate cancer as me-
dian (inter-quartile range) and all comorbidities as pro-
portions. We used Cox proportional-hazards models to
calculate hazard ratios for associations between the dif-
ferent groups and the outcomes. The follow-up time to
fracture was censored for death, emigration or end of
study period. In the final multivariable models, estimated
Table 1 Clinical characteristics









Age, years (mean ± SD) 79 ± 8.0 79 ± 7.4 82 ± 7.0
BMI kg/m2 (mean ± SD) 26 ± 4.6 26 ± 4.2 25 ± 4.3
Follow-up time, years (median; IQR) 1.3 (0.5–2.3) 1.3 (0.5–2.3) 0.8 (0.3–1.7)
General health description
General condition
(good or fairly good)
142,822 (90%) 11,860 (91%) 5916 (86%)
Nutrition (3/4 portion or more) 135,822 (86%) 11,146 (85%) 5353 (78%)
Drinking (> 700 ml/day) 146,157 (92%) 12,134 (93%) 6210 (90%)
Inclusion site
Hospital 111,608 (70%) 10,196 (78%) 4863 (70%)
Nursing home 30,146 (19%) 1630 (12%) 1135 (16%)
Residential home service 7548 (4.7%) 534 (4.1%) 486 (7.0%)
Primary care centre 5659 (3.5%) 447 (3.4%) 244 (3.5%)
Rehab unit 4664 (2.9%) 321 (2.4%) 224 (3.2%)
Previous events
Any fracture 35,731 (22%) 2736 (21%) 1844 (27%)
Hip fracture 9002 (5.6%) 593 (4.5%) 485 (7.0%)
Major osteoporotic fracture 18,906 (12%) 1426 (11%) 1054 (15%)
Comorbidities
Rheumatoid arthritis 2749 (1.7%) 219 (1.7%) 85 (1.2%)
Dementia 14,435 (9.0%) 1127 (8.6%) 620 (8.9%)
Neurological diseases 49,742 (31%) 4931 (38%) 2442 (35%)
Hypertension 70,783 (44%) 7232 (55%) 3797 (55%)
Ischaemic heart disease 44,896 (28%) 4251 (32%) 2379 (34%)
Heart arrhythmias 44,340 (28%) 4211 (32%) 3281 (34%)
Congestive heart failure 29,576 (19%) 2586 (20%) 1603 (23%)
Stroke 27,696 (17%) 2313 (18%) 1206 (17%)
Chronic obstr. pulmonary disease 13,441 (8.4%) 1136 (8.7%) 633 (9.1%)
Chronic liver disease 2244 (1.4%) 150 (1.1%) 67 (1.0%)
Renal failure 13,229 (8.3%) 1323 (10%) 836 (12%)
Type 2 diabetes 34,559 (22%) 2371 (18%) 1332 (19%)
Medications
Glucocorticoids 17,076 (11%) 1564 (12%) 1365 (20%)
Alendronate 4951 (3.1%) 462 (3.5%) 282 (4.1%)
Calcium + vitamin D 9401 (5.9%) 868 (6.6%) 765 (11%)
Antiandrogen 684 (0.4%) 3122 (24%) 5371 (77%)
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available “traditional risk factors” (age, height, weight,
previous fracture, glucocorticoid use, rheumatoid arthritis
secondary osteoporosis and estimated over-consumption
of alcohol) were forced in to the models together with
Charlson comorbidity index, Alendronate, Calcium + vi-
tamin D and self-reported risk of falling (previous fall
yes/no in the Senior Alert questionnaire). Within the sep-
arate patient groups, we performed another Cox
proportional-hazards model where traditional risk factors
including calcium-vit D, Charlson comorbidity index and
self-reported risk of falling were forced into the model.
An extension of Poisson regression models [26] was
used to study the association between potential predictors
and the future risk of fracture. All associations were adjust-
ed for age and time since baseline. In contrast to logistic
regression, the Poisson regression uses the length of each
individual’s follow-up period and the hazard function is
assumed to be exp. (β0 + β1 current time from baseline +
β2 current age + β3 variable of interest). The observation
period of each participant was divided into intervals of
1 month. One fracture per person and time to the first
fracture were counted, and time at risk was censored at
the time of first fracture, loss to follow-up, death or end
of follow-up. Since the current time, since baseline and
current age are used in the model, i.e. the age at each time
of follow-up, not the age at baseline, the model is taking
care of competing risk.
The association between predictive factors and risk of
fracture is described as a hazard ratio (HR) per 1 unit
change in predictor together with 95% confidence inter-
vals (CI). A two-sided p value was used for all analyses
and p < 0.05 was considered to be significant.
Results
Baseline characteristics
In total, we identified 159,662 patients without prostate cancer
and 20,082 patients with prostate cancer. Among those with
prostate cancer, 6954 patients were treated with ADT and
13,128 were not. In patients with ADT, the median treatment
time with GnRH-agonist was 3.7 years (inter-quartile range
1.7–6.0), and more than 90% of the patients had been pre-
scribed their last dose within 3 months.
The median (inter-quartile range) time since diagnosis of
prostate cancer was similar in those with ADT (16 years (8.6–
22)) compared to those without ADT (16 years (8.3–22)).
Baseline characteristics of all patient groups are pre-
sented in Table 1. In summary, patients with ADT were
older, had lower BMI and a shorter follow-up time com-
pared to the other groups. Furthermore, ADT was associ-
ated to a larger proportion of patients considered as in
poorer general condition at inclusion, and a larger propor-
tion of patients had deficiencies in nutrition- and drinking
status. Regarding comorbidities, patients with ADT had a
larger proportion of patients with ischemic heart disease,
heart arrhythmias, congestive heart failure, and renal fail-
ure compared to patients without ADT and compared to
patients without prostate cancer.
At inclusion in the registry, patients with ADT had suffered
from more previous fractures (any fracture, hip fracture or
MOF) compared to all other patients.
Seventy-seven percent of the patients with ADT had been
prescribed antiandrogen, and 20% had received per oral glu-
cocorticoid therapy > 3 months in comparison to 12% in all
Table 2 Incident events in the cohort
Patients without prostate cancer Prostate cancer
without ADT p value with ADT p value** p value***
Patients–no. 159,662 13,128 6954
Time at risk, days–median (IQR) 463 (190–833) 469 (196–843) 279 (95–614)
Total follow-up time–patient-years 242,159 20,246 7721
Any fracture–no. (%) 9644 (6.0%) 732 (5.6%) 0.032 540 (7.8%) < 0.001 < 0.001
Any fracture/1000 patient-years 42 37 74
Hip fracture–no. (%) 4293 (2.7%) 322 (2.5%) 0.110 245 (3.5%) < 0.001 < 0.001
Hip fracture/1000 patient-years 18 16 32
MOF–no. (%) 5663 (3.5%) 455 (3.5%) 0.656 333 (4.8%) < 0.001 < 0.001
MOF/1000 patient-years 24 23 45
Non-skeletal fall injury–no. (%) 7102 (4.4%) 552 (4.2%) 0.201 320 (4.6%) 0.535 0.190
Non-skeletal fall injury/1000 patient-years 30 28 43
Death–no. (%) 54,723 (34%) 4152 (32%) < 0.001 4086 (59%) < 0.001 < 0.001
**Compared to patients without prostate cancer; ***Compared to patients with prostate cancer without ADT
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other patients with prostate cancer and 11% of those without
prostate cancer. Only 4.1% of the patients with ADT had ever
been prescribed alendronate, compared to 3.5% of patient
with prostate cancer but without ADT and 3.1% in patients
without prostate cancer. Other osteoporosis drugs were ex-
tremely rare and are not presented in patient characteristics.
Incident events
Among patients with prostate cancer and ADT, 59% died
during follow-up compared to 32% of all other patients with
prostate cancer and 34% of those without prostate cancer.
ADT was related to higher rates of any incident fracture, hip
fracture and MOF compared to all other patients (Table 2).
The rates for hip fracture and MOF per 1000 patient-years
were 32 and 45 in patients with ADT compared to 16 and 23
in those with prostate cancer but without ADT and 18 and 24
in patients without prostate cancer.
The crude and adjusted hazard ratios for risk of fractures in
prostate cancer patients compared to patients without prostate
cancer are presented in Table 3. In summary, patients with
ADT had increased risk of any fracture (adjusted HR 95%
CI 1.40 (1.28–1.53)), hip fracture (1.38 (1.20–1.58)) and of
MOF (1.44 (1.28–1.61)) compared to patients without
prostate cancer. In comparison to patients with prostate cancer
but without ADT, patients with ADT had increased risk of any
fracture (adjusted HR 95% CI 1.34 (1.19–1.50)), hip fracture
(1.38 (1.16–1.65)) and of MOF (1.34 (1.16–1.56)). The ad-
justed survival curves for hip fracture and MOF in patients
with prostate cancer and ADT compared to patients without
prostate cancer are presented in Fig. 2a, b.
In a Cox-regression analysis adjusted for age, weight,
height and Charlson comorbidity index, treatment with ADT
was not significantly associated to incident risk of non-
skeletal fall injury compared to those without ADT (1.15
(1.00–1.32) or compared to those without prostate cancer
(1.01 (0.90–1.13).
Among patients with prostate cancer, known prescription of
antiandrogens where related to any incident fracture in a model
adjusted for age and BMI (HR 95%CI 1.27 (1.14–1.42).When
the variable GnRH-agonists (current ADT) was entered into the
model, the relationship between antiandrogens and the out-
come was no longer significant (1.08 (0.95–1.22).
Analysis of competing risk
An extension of Poisson regression models was used to study
the association between potential predictors and the future risk













p value Compared to patients
without prostate cancer




Any fracture (HR (95% CI))
Age, height, weight Reference 0.94 (0.87–1.01) 0.111 1.46 (1.34–1.59) < 0.001 1.51 (1.35–1.70) < 0.001
Traditional risk factors* Reference 0.96 (0.89–1.04) 0.322 1.42 (1.30–1.54) < 0.001 1.44 (1.2748–1.61) < 0.001
Multivariate** Reference 0.97 (0.90–1.05) 0.449 1.40 (1.28–1.53) < 0.001 1.34 (1.19–1.50) < 0.001
MOF (HR (95% CI))
Age, height, weight Reference 1.02 (0.92–1.12) 0.756 1.55 (1.39–1.73) < 0.001 1.50 (1.30–1.73) < 0.001
Traditional risk factors* Reference 1.03 (0.94–1.14) 0.514 1.51 (1 35–1 69) < 0.001 1.44 (1.24–1.66) < 0.001
Multivariate** Reference 1.01 (0.92–1.12) 0.802 1.44 (1.28–1.61) < 0.001 1.34 (1.16–1.56) < 0.001
Hip fracture (HR (95% CI))
Age, height, weight Reference 0.96 (0.86–1.08) 0.519 1.48 (1 30–1 69) < 0.001 1.51 (1.28–1.79) < 0.001
Traditional risk factors* Reference 0.97 (0.87–1.09) 0.642 1.46 (1.28–1.66) < 0.001 1.46 (1.24–1.74) < 0.001
Multivariate** Reference 0.95 (0.84–1.07) 0.355 1.38 (1.20–1.58) < 0.001 1.38 (1.16–1.65) < 0.001
Non-skeletal fall injury (HR (95%CI))
Age, height, weight Reference 0.96 (0.88–1.05) 0.332 1.20 (1.07–1.34) 0.001 1.21 (1.05–1.40) 0.007
Age, height, weight and Charlson Reference 0.84 (0.77–0.92) < 0.001 1.01 (0.90–1.13) 0.920 1.15 (1.00–1.32) 0.057
*Previous fracture, glucocorticoid use, rheumatoid arthritis, estimated over consumption of alcohol, and secondary osteoporosis
**Previous fracture, glucocorticoid use, rheumatoid arthritis, estimated over consumption of alcohol, secondary osteoporosis, Charlson, alendronate,
calcium + vitamin D and previous known fall (yes/no)
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of fracture. The current time since baseline was used in the
model, i.e. the age at each time of follow-up, not the age at
baseline, thus the model was taking care of competing risk. In
these models, there was no relevant interaction between time
since baseline and risk of the outcomes in any of the patient
groups. However, we found a significant interaction between
age and risk of fracture where the differences in risk were larger
in younger patients. This was most evident among young pa-
tients with prostate cancer with and without ADT. From the
models, hazard ratios according to specified ages (70, 80 and
90 years) were calculated and are presented in Table 4.
Risk factors models within the patient groups
Within the three groups of patients, we performed Cox
proportional-hazards models where “traditional risk factors”
were forced together including known prescription of
calcium/vitamin D, Charlson comorbidity index and self-
reported history of falling. The final models are presented in
Table 5. The pattern of importance among the selected risk
factors was similar in all groups where age, low BMI, previ-
ous fracture and previous falls remained highly significant in
all patient groups.
Fig. 2 Survival curves of time to
hip fracture (a) and major
osteoporotic fracture (b) in
patients with prostate cancer and
GnRH-agonist compared to
patients without prostate cancer
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Discussion
In this large Swedish cohort of elderly male patients, we found
that patients with prostate cancer and treatment with ADT had
increased risk of incident fractures. The results were signifi-
cant for any fracture, MOF and hip fracture in multivariate
models compared to those with prostate cancer without ADT
and compared to those without prostate cancer.
During the past decade, several epidemiological studies
have presented relationships between ADT and an increased
risk of incident fractures. One large study of more than 50,000
menwith prostate cancer showed that within 5 years, 19.4% of
those with ADT sustained a fracture, compared to 12.6% of
those without ADT [14]. Another study of 3779 men with
prostate cancer who received treatment with a GnRH agonist
had a relative risk of 1.76 for hip fracture compared to a
control group of 8341 with prostate cancer who were not
treated with a GnRH agonist [15]. In a large matched cohort
study of almost 20,000 men with prostate cancer and ADT,
matched with “non-users”, the HR for hip fracture was 1.65
for fragility fracture in the group with ADT [16].
In comparison to these previous studies, our results originate
from a very large cohort of older men with and without prostate
cancer with a large number of incident fractures. All patients in
the cohort, including those without prostate cancer, were pa-
tients with high risk of osteoporotic fractures with a mean age
of approximately 80 years and a large proportion had already
suffered from a previous fracture. Thus, according to our re-
sults, the patients with prostate cancer and ADT truly represent
an easily detected group with a very high risk of osteoporotic
fractures. Furthermore, we have been able to adjust statistically
not only for medical treatments such as any prescriptions of
alendronate and calcium and vitamin D-supplements but also
for established risk factors such as BMI, previous fractures,
glucocorticoid treatment and rheumatoid arthritis, which re-
semble parameters in known risk calculators. Thus, the present
study implicates that treatment with ADT increases the risk for
fractures independently of many of the traditional risk factors
Table 4 Crude hazard ratios
(95% CI) shown for ages 70, 80
and 90 years in the patient groups
according to a Poisson regression
model












Any fracture Interaction term p < 0.001 Interaction term p = 0.12 Interaction term
p < 0.001
70 0.63 (0.53, 0.75)* 1.66 (1.33, 2.07)* 2.63 (1.99, 3.48)*
80 0.83 (0.75, 0.93)* 1.49 (1.31, 1.71)* 1.79 (1.50, 2.13)*
90 1.11 (0.97, 1.26) 1.35 (1.16, 1.56)* 1.22 (1.00, 1.48)*




70 0.55 (0.41, 0.74)* 2.15 (1.53, 3.02)* 3.89 (2.51, 6.02)*
80 0.80 (0.66, 0.96)* 1.63 (1.33, 1.99)* 2.04 (1.56, 2.67)*
90 1.15 (0.95, 1.39) 1.23 (0.99, 1.53) 1.07 (0.81, 1.42)




70 0.70 (0.56, 0.88)* 2.09 (1.58, 2.77)* 2.99 (2.09, 4.26)*
80 0.93 (0.80, 1.08) 1.64 (1.39, 1.95)* 1.76 (1.41, 2.20)*
90 1.24 (1.05, 1.46)* 1.29 (1.07, 1.56)* 1.04 (0.82, 1.33)
Non-skeletal fall
injury
Interaction term p < 0.001 Interaction term p > 0.30 Interaction term p = 0.12
70 0.71 (0.58, 0.86)* 0.97 (0.72, 1.31) 1.38 (0.98, 1.95)
80 0.88 (0.77, 1.01) 1.03 (0.86, 1.24) 1.17 (0.94, 1.45)
90 1.11 (0.94, 1.30) 1.10 (0.90, 1.33) 0.99 (0.78, 1.26)
*p < 0.001. An extension of Poisson regression models was used to study the association between potential
predictors and the future risk of fracture. The observation period of each participant was divided into intervals
of 1 month. One fracture per person and time to the first fracture were counted, and time at risk was censored at the
time of first fracture, loss to follow-up, death or end of follow-up. Since the current time, since baseline and
current age are used in the model i.e. the age at each time of follow up, not the age at baseline, the model is taking
care of competing risk. The association between predictive factors and risk of fracture is described as a hazard
ratio (HR) at baseline of the study, per 1 unit change in predictor together with 95% confidence intervals (CI)
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[27]. The final models were also adjusted for self-reported risk
of falling (previous fall yes/no), which is a unique information
in such a large cohort when studying risk for fractures.
We also detected an interaction between the different pa-
tient groups, the risk of fracture and age where for example a
fictive 70-year-old patient with prostate cancer and ADT had
an almost fourfold risk of hip fracture compared to a 70-year-
old patient without ADT. Correspondently, we found that the
70-year-old patient with prostate cancer but without ADT had
in fact a much lower risk for incident fractures compared to
patient without prostate cancer, thus representing a low-risk
subgroup compared to the general population. We believe that
the interaction with age mirrors the increased fracture risk
among the elderly in general (for multifactorial reasons) which
contributes to smaller differences among the oldest old in
statistical analyses. However, it is very important for urologist
to comprehend that these two 70-year-old prostate cancer pa-
tients are to be regarded as completely different regarding
fracture risk and those with ADT must be mandatorily evalu-
ated regarding osteoporosis and antiresorptive medications.
Since the diagnosis of osteoporosis is very rarely used in
the Swedish patient register (and extremely few patients are
evaluated regarding osteoporosis in real life), we did not have
reliable information regarding bone health in the dataset.
Nevertheless, the relationship between treatment with ADT
and osteoporosis has been known for almost 20 years and
was recently presented in a meta-analysis of studies in
prostate-cancer survivors [11]. In the same analysis, most of
the ADT-patients were classified as either osteopaenic or os-
teoporotic (up to 85.0%), and the variation in the prevalence
of osteoporosis in different studies (9.0–53.0%) was mainly
influenced by ADT duration, disease stage, ethnicity and
skeletal site used to diagnose osteoporosis. Furthermore, in
one study, 618 men initiating ADT for prostate cancer were
prospectively recruited and followed for 7 years. The preva-
lence of osteopenia and osteoporosis was very high already at
treatment start in these patients (39% and 41%, respectively),
leaving only 20% with normal bone density. A large propor-
tion of the patients decreased their T-score by 1.0 and, after
3 years at least half of the patients who had a normal or
osteopaenic BMD at treatment start had tripled their fracture
risk [28]. Indeed, there is a rapid bone loss during the first 6–
12 months of therapy [12] and this implicates the importance
of detecting these patients at an early stage.
The Swedish population is characterised by one of the
highest incidences of hip fracture in the world [29], and studies
have shown that in Sweden, second to stroke, osteoporotic
fractures account for more hospital-bed days yearly than any
other diagnose [30]. In the present study, we found almost
11,000 fractures; and among these, almost 5000 were hip frac-
tures. This is important since the hip fracture is indeed the most
severe of the osteoporotic fractures and is associated with in-
creased mortality in the general population [5]. An analysis
based on the national Swedish Prostate Cancer Registry con-
firms that this is particularly true for men on ADT, with a two-
times increase in deaths per 1000 person-years after hip fracture
compared to the general male population [31].
Other known metabolic complications that are related to
ADT are sexual dysfunction, gynecomastia, sarcopenia (re-
duced lean body mass) and body composition changes that
may increase the risk of metabolic syndrome. This in turn
impacts on fitness and the risk of falls may increase [11, 32].
However, in the present study, we did not see a significant
relationship between treatment with ADT and the risk of
Table 5 Multivariate risk factor models within the separate groups
Multivariate risk factor model* Patients without prostate cancer
(n = 159,662)
Prostate cancer without ADT
(n = 13,128)
Prostate cancer with ADT
(n = 6954)
Age (years) 1.05 (1.04–1.05) p < 0.001 1.07 (1.06–1.08) p < 0.001 1.04 (1.02–1.05) p < 0.001
BMI (kg/m2) 0.96 (0.95–0.96) p < 0.001 0.97 (0.95–0.99) p = 0.001 0.96 (0.94–0.98) p = 0.001
Previous fracture 1.99 (1.90–2.07) p < 0.001 2.53 (2.17–2.95) p < 0.001 1.94 (1.63–2.31) p < 0.001
Reumatoid arthritis 1.18 (1.02–1.37)) p = 0.26 1.63 (1.02–2.60) p = 0.042 1.56 (0.84–2.90) p = 0.157
Cortisone 1.09 (1.01–1.17) p = 0.19 1.06 (0.83–1.36) p = 0.626 0.92 (0.71–0.19) p = 0.534
Secondary osteoporosis 1.31 (1.20–1.42) p < 0.001 1.32 (0.94–1.84) p = 0.107 1.20 (0.78–1.83) p = 0.412
Estimated alcohol over consumption 1.67 (1.49–1. 86) p < 0.001 1.28 (0.79–2.05) p = 0.315 0.70 (0.29–1.70) p = 0.426
Calcium + vitamin D 0.95 (0.88–1.04) p = 0.274 1.07 (0.82–1.41) p = 0.619 1.22 (0.93–1.61) p = 0.155
Charlson morbidity index 1.00 (0.99–1.01) p = 780 1.08 (1.04–1.10) p < 0.001 1.04 (1.01–1.07) p = 0.009
Previous fall 1.69 (1.62–1.76) p < 0.001 1.75 (1.51–2.04) p < 0.001 1.34 (1.12–1.60) p = 0.001
*Age (years), BMI (kg/m2), previous fracture (y/n), rheumatoid arthritis (according to ICD), cortisone (any previous period the patient had retrieved
prescriptions for more than 450 mg of prednisolone or equivalents over a period of 3 months or more, a dose corresponding to a daily treatment with at
least 5 mg prednisolone for 3 months), secondary osteoporosis (secondary osteoporosis was defined as the presence of diagnoses of insulin dependent
diabetes, hyperthyroidism, hypogonadism, malnutrition, osteogenesis imperfecta or chronic liver disease, estimated alcohol over consumption (over-
consumption of alcohol was estimated according to several diagnoses of alcohol abuse together with alcohol related diseases according to ICD-codes)
Charlson morbidity index, previous fall (y/n)
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non-skeletal fall injury neither in the Cox regression models
nor the Poisson models. This was indeed somewhat surprising
as the relationship between ADT and the risk of fracture was
strongly significant and implies that the effect of ADT on
fracture incidence is primarily mediated through skeletal
changes. To our knowledge, this is the first study in such a
large cohort where non-skeletal fall injury could be investigat-
ed together with fractures. This strengthens the indications for
bone-specific medical treatments of this group. However, in
Sweden, a devastating small proportion of high-risk patients is
normally considered for osteoporotic medications and only
3% of men, aged 50 or more with a previous fragility fracture
are offered medical treatment [33]. In the present study, a very
small proportion (only 4%) of the patients with ADT had ever
been prescribed alendronate although almost a third had suf-
fered from a previous fracture. One may speculate that by the
time this cohort was collected (2008–2014), little attention
was given to bone health in this patient group. Furthermore,
given the fact that the patient with ADT generally suffers from
other side-effects, as stated previously, very few patients (or
physicians) may be concerned about the silent disorder of
osteoporosis. However, during the past years, the research
field of the efficacy of osteoporotic medications in this patient
group has increased. A recently published meta-analysis pre-
sented that both oral and intravenous bisphosphonates and
denosumab were effective in reducing the rate of bone loss
when compared to placebo. Furthermore, patients who re-
ceived denosumab had a decreased incidence of new vertebral
fractures at 36 months (1.5%, vs. 3.9% with placebo, RR =
0.38; p = 0.006) [34, 35]. In the present study, there were too
few patients prescribed both alendronate and ADT in order to
do any statistical calculations. However, we have recently
presented another study from the same original cohort, where
alendronate significantly reduced the risk of incident fractures
(HR 0.66, p < 0.01) and even reduced mortality in men and
women (80 years or older) with a previous fracture [20].
There are limitations with this study. We did not have ac-
cess to measurements of BMD, smoking or alcohol use in the
databases and vertebral fractures that are often bypassed and
not diagnosed in registers could not be reliably studied in this
cohort. On the other hand, we estimate that largely all hip
fractures were detected since this diagnosis is established at
emergency units and hospital wards, all connected to the na-
tional registers. Furthermore, we did not have any detailed
clinical information regarding their prostate cancer such as
Gleason score. One strength of this study is that we have
indeed BMI and self-reported information on previous falls
which are unique features of such a large database and of great
importance in studies of fracture risk.
In conclusion, our results confirm that patients with pros-
tate cancer and ADT have increased risk of incident osteopo-
rotic fractures. This was significant also after multivariate ad-
justment for traditional fracture-related risk factors, and the
differences in risk were most prominent in younger patients
where the treatment with ADT contributed to an almost four-
fold risk of incident hip fracture compared to those with pros-
tate cancer but without ADT.We also found that there were no
clinically relevant relationships between treatment with ADT
and incident non-skeletal fall injury which further strengthens
the assumption that the relationship between ADTand fracture
is primarily bone-related. Although all patients with prostate
cancer and ADT should be considered as “high risk patients”,
we found that within this group, the only clinically relevant
risk factors for incident fracture were high age, low BMI,
previous fracture and/or previous falls and other traditional
risk factors did not contribute significantly in the statistical
models. We believe that further effort in acknowledging this
fragile patient group must be taken and that osteoporosis med-
ications should be considered as routine procedures in all pa-
tients with prostate cancer already at the initiation of androgen
deprivation therapy.
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